Peritoneal Cancer
📧 Sign up to get email alerts when something new happens for Peritoneal Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-08-11Clinical Trial Update: Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer [Phase 2]
Takeda-sponsored Phase 2 trial of Niraparib in advanced, relapsed ovarian cancer (including fallopian tube and primary peritoneal cancers) h…
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer [Phase 3]
Phase 3 trial evaluating paclitaxel and carboplatin versus ifosfamide in newly diagnosed, persistent, or recurrent uterine, ovarian, fallopi…
-
CLINICAL_TRIALS trial_result · 2020-07-22Clinical Trial Update: Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer [Phase 1, Phase 2]
This trial update reports Phase 1/2 results for the combination of cediranib and olaparib in recurrent ovarian, fallopian tube, or primary p…
-
CLINICAL_TRIALS trial_result · 2020-07-09Clinical Trial Update: A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers [EARLY_Phase 1]
Early-phase study evaluating pembrolizumab in gynecologic cancers; study completed with results posted in 2020.
-
FDA approval · 2020-05-15FDA Approved: RUBRACA — Supplemental Application (pharmaand GmbH)
The FDA approved a supplemental application for RUBRACA (rucaparib) submitted by pharmaand GmbH.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-05-04Clinical Trial Update: Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer [Phase 1, Phase 2]
Phase I/IIa trial update for a folate binding protein vaccine in ovarian cancer, with completed status across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-04-08Clinical Trial Update: Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating erlotinib in combination with carboplatin for recurrent ovarian, fallopian tube, or primary peritoneal cancer compl…
-
CLINICAL_TRIALS trial_result · 2020-03-25Clinical Trial Update: Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer [Phase 2]
Takeda-sponsored phase 2 trial evaluating niraparib as maintenance therapy in Japanese participants with relapsed ovarian cancer has complet…
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]
Phase 2 trial evaluating cabozantinib versus paclitaxel for persistent or recurrent epithelial ovarian, fallopian tube, or primary peritonea…
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial update for tivozanib in recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer has completed with …
-
CLINICAL_TRIALS withdrawal · 2020-02-24Clinical Trial Update: Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission [Phase 3]
Phase 3 clinical trial evaluating a vaccine therapy with OPT-821 in ovarian epithelial, fallopian tube, or primary peritoneal cancer was wit…
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma [Phase 3]
A Phase 3 trial comparing tri-weekly TJ to weekly TJ in stage II-IV Mullerian carcinoma (epithelial ovarian cancer and related cancers) has …
-
CLINICAL_TRIALS trial_result · 2019-12-18Clinical Trial Update: Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial update evaluating AMG 386 in combination with Paclitaxel for advanced recurrent epithelial ovarian cancer and related…
-
CLINICAL_TRIALS trial_result · 2019-12-10Clinical Trial Update: Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer [Phase 3]
Phase 3 clinical trial assessing reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, and primar…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating adavosertib in combination with chemotherapy for platinum-resistant epithelial ovarian, fallopian tube, or primary …
-
CLINICAL_TRIALS trial_result · 2019-11-08Clinical Trial Update: A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer [Phase 1]
Phase 1b study of paclitaxel with ricolinostat for gynecologic cancer was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery [Phase 3]
A Phase 3 clinical trial evaluating the efficacy of HIPEC following cytoreductive surgery for advanced epithelial ovarian cancer (including …
-
CLINICAL_TRIALS trial_result · 2019-10-18Clinical Trial Update: Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer [Phase 2]
Phase 2 trial update evaluating ribociclib plus letrozole in relapsed estrogen receptor-positive cancers of female reproductive tract (ovari…
-
CLINICAL_TRIALS trial_result · 2019-10-02Clinical Trial Update: Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer [Phase 2]
A Phase 2 trial comparing standard infusion carboplatin to prophylactic extended infusion carboplatin in recurrent ovarian, fallopian tube, …
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating VTX-2337 with pegylated liposomal doxorubicin in recurrent or persistent epithelial ovarian, fallopian tube, or pri…
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer [Phase 1, Phase 2]
Clinical trial update for ganetespib (GANNET53) in metastatic p53-mutant platinum-resistant ovarian cancer; trial terminated with posted res…
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable [Phase 2]
Phase 2 study evaluating neoadjuvant bevacizumab (Avastin) in patients with initially unresectable FIGO stage IIIC/IV ovarian, tubal, or per…
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer [Phase 2]
Phase 2 clinical trial update for vorinostat in recurrent or persistent ovarian epithelial cancer and primary peritoneal cancer.
-
FDA approval · 2019-06-27FDA Approved: ZIRABEV — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves ZIRABEV (bevacizumab-bvzr) from Pfizer as a biosimilar to Avastin under an Original Application. The approval covers multiple b…
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: A Study LY2228820 for Recurrent Ovarian Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial update for LY2228820 in recurrent ovarian cancer (epithelial ovarian cancer, fallopian tube cancer, primary perit…